#Canada #Salt Lake City #Lipocine #TLANDO #Verity Pharmaceuticals

TLANDO: A New Era in Testosterone Replacement Therapy in Canada

On October 7, 2026, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in the development of innovative oral therapeutics, announced a pivotal milestone in men’s health: Health Canada has officially approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males experiencing conditions related to a deficiency or absence of endogenous testosterone, known medically as male hypogonadism. This development signals a new chapter not only for Lipocine but also for men across Canada who face the challenges of testosterone deficiency.

Partnering for Progress

This significant achievement comes through Lipocine's licensing partner, Verity Pharmaceuticals Inc., which holds exclusive commercial rights for TLANDO in North America. Verity Pharma is gearing up for the launch and commercialization of TLANDO in the Canadian market, expected by the end of 2026.

Dr. Mahesh Patel, President and CEO of Lipocine, expressed enthusiasm for the approval, stating, "This marks a major step in expanding the geographic reach of TLANDO. Men with low testosterone in Canada have primarily relied on injections and topical gels, and TLANDO now offers them a convenient oral option." He added that the approval reinforces Lipocine’s successful commercial strategy in partnership with Verity.

A Solution to Common Challenges in TRT

Dr. Neil Flesher, Chief Medical Officer at Verity Pharma, emphasized the unique advantages TLANDO provides to patients and healthcare providers. TLANDO's simple, fixed dosing regimen alleviates the complications often associated with starting and managing testosterone therapy, such as dose titration and compliance challenges. This can significantly simplify the therapeutic journey for both physicians and their patients.

The Canadian testosterone replacement therapy (TRT) market represents a vast opportunity, with over 700,000 prescriptions written annually, half of which are covered by private insurance. The current reliance on intramuscular injections and topical gels, which come with their own challenges (like messy application or transference issues), highlights a strong demand for a safe, effective oral alternative. TLANDO's streamlined dosing may not only improve patient convenience but also compliance, potentially leading to better therapeutic outcomes.

Understanding the Use and Safety of TLANDO

Approved by Health Canada, TLANDO is indicated for adult males with hypogonadism associated with low endogenous testosterone levels. Nevertheless, it’s essential to note that TLANDO should not be used to treat non-specific symptoms suggestive of hypogonadism unless testosterone deficiency is properly diagnosed and confirmed by clinical features and validated biochemical assays.

Lipocine reminds patients that while TLANDO aims to restore testosterone levels, it is contraindicated for those with known hypersensitivity to its components and should be utilized with caution, considering the risks of side effects and the importance of proper medical guidance in its administration.

Additional Therapeutic Potential in Men’s Health

Lipocine Inc. is also deepening its commitment to addressing unmet medical needs through its diverse development pipeline, which includes candidates for conditions ranging from postpartum depression to epilepsy. However, TLANDO stands out as a pivotal product in their portfolio, aiming to reshape the landscape of testosterone replacement therapies available in Canada.

Conclusion

The approval of TLANDO by Health Canada signifies not just a regulatory win for Lipocine and its partners but offers a much-needed solution for adult men dealing with the often-overlooked ramifications of testosterone deficiency. As Verity prepares for the upcoming launch, the anticipation grows to see how TLANDO will transform the TRT landscape in Canada, ultimately benefiting countless patients seeking reliable and effective treatment.

For more information on Lipocine and its innovative therapies, one can visit Lipocine’s website.